Overview
Schizoaffective disorder is a chronic mental health condition characterized by symptoms of schizophrenia, such as hallucinations or delusions, and mood disorder symptoms, such as depression or mania 1. The condition requires continuous treatment to manage symptoms and improve functioning 1.Diagnosis
No diagnostic criteria or recommended tests are covered in the provided abstracts.Management
Second-generation antipsychotics (SGAs) are used for schizophrenia 1.
Olanzapine and risperidone are associated with the greatest weight gain 1.
Olanzapine is associated with the largest BMI increase 1.
Paliperidone is associated with the highest increase in total cholesterol, but also the only drug reporting an increase in HDL cholesterol 1.
Quetiapine XR is associated with the highest increase in systolic and diastolic blood pressure 1.
Lurasidone is associated with the lowest increase in body weight, a reduction in BMI, and a decrease in total cholesterol and triglycerides 1.Special Populations
No information on special populations is covered in the provided abstracts.Key Recommendations
Second-generation antipsychotics (SGAs) for schizophrenia have varying risk profiles for metabolic and cardiovascular side effects 1.
Olanzapine and risperidone are associated with significant weight gain 1.
Lurasidone demonstrates a favorable metabolic profile with minimal weight gain and reductions in cholesterol and triglycerides 1.
Quetiapine XR may increase blood pressure 1.
Paliperidone is associated with increased total cholesterol but also an increase in HDL cholesterol 1.References
1 Rognoni C, Bertolani A, Jommi C. Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects. Clinical drug investigation 2021. link